Gilead Sciences, Inc. (NASDAQ:GILD) CFO Sells $275,425.00 in Stock

Gilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $110.17, for a total transaction of $275,425.00. Following the completion of the sale, the chief financial officer now owns 165,110 shares in the company, valued at approximately $18,190,168.70. This trade represents a 1.49% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Gilead Sciences Stock Down 2.6%

GILD traded down $2.83 on Tuesday, hitting $108.00. 5,601,061 shares of the company were exchanged, compared to its average volume of 7,738,479. The company has a current ratio of 1.37, a quick ratio of 1.23 and a debt-to-equity ratio of 1.16. The company has a market cap of $134.34 billion, a price-to-earnings ratio of 22.74, a price-to-earnings-growth ratio of 0.72 and a beta of 0.29. The firm has a 50-day moving average price of $105.82 and a two-hundred day moving average price of $102.45. Gilead Sciences, Inc. has a twelve month low of $62.69 and a twelve month high of $119.96.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, topping analysts' consensus estimates of $1.77 by $0.04. The firm had revenue of $6.67 billion for the quarter, compared to analyst estimates of $6.77 billion. Gilead Sciences had a net margin of 20.76% and a return on equity of 51.93%. The business's quarterly revenue was down .3% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.32) earnings per share. On average, equities analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 27th. Shareholders of record on Friday, June 13th will be paid a $0.79 dividend. The ex-dividend date of this dividend is Friday, June 13th. This represents a $3.16 annualized dividend and a yield of 2.93%. Gilead Sciences's dividend payout ratio is currently 66.53%.

Institutional Trading of Gilead Sciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Brighton Jones LLC boosted its holdings in shares of Gilead Sciences by 20.6% in the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company's stock valued at $1,326,000 after acquiring an additional 2,450 shares during the period. Everhart Financial Group Inc. acquired a new position in shares of Gilead Sciences during the fourth quarter worth about $239,000. Principal Securities Inc. boosted its holdings in Gilead Sciences by 45.0% in the 4th quarter. Principal Securities Inc. now owns 14,404 shares of the biopharmaceutical company's stock valued at $1,330,000 after purchasing an additional 4,468 shares in the last quarter. Allworth Financial LP raised its stake in shares of Gilead Sciences by 24.8% during the 4th quarter. Allworth Financial LP now owns 35,953 shares of the biopharmaceutical company's stock worth $3,345,000 after buying an additional 7,143 shares in the last quarter. Finally, J.W. Cole Advisors Inc. lifted its holdings in shares of Gilead Sciences by 1.0% in the 4th quarter. J.W. Cole Advisors Inc. now owns 13,597 shares of the biopharmaceutical company's stock valued at $1,256,000 after buying an additional 135 shares during the period. Institutional investors and hedge funds own 83.67% of the company's stock.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the company. Wells Fargo & Company raised their target price on Gilead Sciences from $120.00 to $140.00 and gave the company an "overweight" rating in a research report on Wednesday, March 5th. Morgan Stanley increased their target price on shares of Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a research report on Friday, April 25th. Deutsche Bank Aktiengesellschaft upgraded Gilead Sciences from a "hold" rating to a "buy" rating and boosted their target price for the stock from $80.00 to $120.00 in a report on Tuesday, February 18th. Oppenheimer lowered their price target on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a research report on Friday, April 25th. Finally, Needham & Company LLC reissued a "hold" rating on shares of Gilead Sciences in a research note on Wednesday, May 21st. Nine research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $110.55.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.